BMRA vs IMRN

The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.

The deterministic health profile is weak, headlined by a Piotroski F-Score of 3/9, indicating significant financial deterioration. While the company maintains a strong liquidity position with a Current Ratio of 8.04 and negligible debt (D/E 0.02), these are offset by severe operational losses and a profit margin of -62.14%. The stock is in a clear long-term downtrend, losing over 85% of its value over five years, and the lack of recent earnings data suggests a lack of transparency or momentum. Despite trading below book value (P/B 0.70), the fundamental decay outweighs the valuation discount.